Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes
批准号:
10450154
负责人:
Lbachir BenMohamed
金额:
$59.97万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-15 至 2024-07-31
关键词:
AntigensBasic ScienceBiologyBone MarrowCCL25 geneCD8-Positive T-LymphocytesCD8B1 geneCXC chemokine receptor 3CXCL10 geneCXCL14 geneCXCL9 geneCXCR3 geneCellsChemotactic FactorsDataDevelopmentDiseaseEpithelial CellsExposure toFemale genitaliaGPR2 geneGenerationsGoalsHerpesviridae InfectionsHomeostasisHomingHuman Herpesvirus 2ImmunityImmunologic SurveillanceImmunotherapyInfectionInflammation MediatorsIntravaginal AdministrationInvestigationKineticsKnowledgeLongevityLymphocyteMaintenanceMediatingMediator of activation proteinMemoryModelingMolecularMucosal ImmunityMucous MembraneMusPeripheralPlayProcessProductionPublishingResearch Project GrantsRoleSimplexvirusSourceT memory cellT-Cell ReceptorT-LymphocyteT-Lymphocyte EpitopesTestingTissuesTranslational ResearchVaccinesVaginaViralViral Antigensbasechemokinechemokine receptorgenital herpesmouse modelnovelnovel vaccinespathogenpathogenic virusreceptorrecruitreproductive tractvaccine strategyvaginal mucosa
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Mucosal tissues are frontline barriers that are continuously exposed to infectious pathogens. Developing and
maintaining protective mucosal tissue-resident memory T cells (TRM cells) is necessary for immune surveillance.
However, the mechanisms controlling homing and maintenance of mucosal TRM cells are unknown and likely
distinct from those regulating conventional circulating effector memory (TEM) and central memory (TCM) cells. A
currently accepted paradigm is that mucosal chemokines (i.e., CCL25, CCL28, CXCL14, and CXCL17) play a
crucial role in mobilizing TRM cells in mucosal tissues, and may occur independent of local antigen recognition.
However, several major gaps remain, including: (1) the identity of the mucosal chemokines involved; (2) their
cellular source; and (3) the cellular and molecular mechanisms through which they regulate mobilization of anti-
viral mucosal CD8+ TRM cells. This proposal uses herpes simplex virus type 2 (HSV-2) as a model viral pathogen
to elucidate the underlying mechanisms that regulate mobilization of HSV-specific CD8+ TRM cells in the vaginal
mucosal tissue. Our published and preliminary data indicate that: (A) Elevated numbers of HSV-specific memory
CD62LlowCCR7lowCD103highCD8+ TRM cells and CXCR8+CD8+ T cells are present in the vaginal mucosa of HSV-
2 infected asymptomatic mice as compared to symptomatic mice; (B) Mucosal chemokines CXCL17 and CCL28
are highly expressed in the vaginal mucosal tissues of HSV-2-infected asymptomatic mice, with no apparent
genital herpes disease; (C) CD8+ TRM cells that reside in vaginal mucosa of asymptomatic mice express CXCR3
(the receptor for T cell-attracting chemokines CXCL9 and CXCL10),CXCR8, and CCR10 (the receptors for
CXCL17 and CCL28, respectively); (D) Intravaginal administration of T cell-attracting chemokines CXCL9 and
CXCL10 is associated with increased recruitment of CXCR8+CD8+, CCR10+CD8+ TRM cells to the vaginal mucosa
of asymptomatic mice; and (E) Exogenous CXCL9 and CXCL10 significantly increased expression of CXCR3,
CXCR8, and CCR10 receptors on vaginal mucosa-resident CD8+ TRM cells. Based on these findings, we
hypothesize that CXCL17 and CCL28 play a crucial role in homing and maintenance of vaginal mucosal tissue-
resident CD8+ TRM cells, which protect from genital herpes. Our Specific Aims include: Aim 1 will identify the
cellular sources of CXCL17 and CCL28 in vaginal mucosa and the mediators that regulate their expression. Aim
2 will investigate the role of CXCL17 and CCL28 mucosal chemokines and study the need for local viral antigen
expression in developing, maintaining, and expanding CD8+ TRM cells within the vaginal mucosa. Aim 3 will
develop a novel “prime, pull, and keep” vaccine strategy to increase the size and maintenance of vaginal mucosa-
resident CD8+ TRM cells to protect against genital herpes. This is based on three sequential steps of intravaginal
administration of: (1) CD8+ T cell epitopes (prime); (2) CXCL9 and/or CXCL10 T-cell attracting chemokines (pull);
and (3) CXCL17 and/or CCL28 mucosal chemokines (keep). Successful completion of this basic and
translational research project will pave the way towards the development of an effective mucosal herpes vaccine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:10318146
-
项目类别:
-
资助金额:$61.29万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10171239
-
项目类别:
-
资助金额:$74.54万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:10546435
-
项目类别:
-
资助金额:$61.29万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:9913971
-
项目类别:
-
资助金额:$69.75万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10231272
-
项目类别:
-
资助金额:$71.8万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10669702
-
项目类别:
-
资助金额:$74.22万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:10083701
-
项目类别:
-
资助金额:$68.49万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10454975
-
项目类别:
-
资助金额:$75.69万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes
-
批准号:10223136
-
项目类别:
-
资助金额:$60.33万
-
财政年份:2019
-
负责人:Lbachir BenMohamed
-
依托单位:
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease
-
批准号:9752627
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2016
-
负责人:Lbachir BenMohamed
-
依托单位:
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease
-
批准号:9183816
-
项目类别:
-
资助金额:$38.81万
-
财政年份:2016
-
负责人:Lbachir BenMohamed
-
依托单位:
LAT-HVEM Interactions Effect HSV-1 Latency/Reactivation
-
批准号:9084450
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2015
-
负责人:Lbachir BenMohamed
-
依托单位:
Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular Herpe
-
批准号:9121574
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2014
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:7986401
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8523888
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8327246
-
项目类别:
-
资助金额:$36.72万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:9112499
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8128628
-
项目类别:
-
资助金额:$36.72万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8710229
-
项目类别:
-
资助金额:$35.99万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing A Tissue-Targeted Ocular HSV Therapeutic Vaccine
-
批准号:10600045
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
海外基金